Sentence examples for evaluating the combinations of from inspiring English sources
The ongoing trials evaluating the combinations of pertuzumab plus T-DM1 and the triple combination of pertuzumab plus T-DM1 plus a taxane are thus well founded [ 64].
Based on the above, we conducted an open-label, parallel-dose escalation study evaluating the combinations of dalotuzumab with MK-0752 MK-2206206 in solid tumours with expansion cohorts in biomarker-positive ovarian and colon cancer patients of these phase I doublets at their RP2Ds, and an additional expansion cohort of ovarian cancer with dalotuzumab and ridaforolimus.
In addition, we measured linkage disequilibrium by D' and R between the three polymorphisms using the UNPHASED program, which showed that the three polymorphism sites were not likely to be linked (R < 0.8).> The results of exhaustive MDR analysis evaluating the combinations of the three tested SNPs are summarized in Table 3.
New trials evaluating the combination of reduced-dose fibrinolytics with different regimens of antithrombotic agents will optimize future reperfusion strategies.
Such contamination can be statistically interpreted and it is very useful due to its relative importance in evaluating the combination of large chemical variable dataset.
We conducted a systematic review and meta-analysis of randomized trials evaluating the combination of an ACE inhibitor and an ARB in patients with chronic proteinuric renal disease.
The importance of evaluating the combination of S. aureus virulence factors has been emphasized both in human and veterinary medicine, and knowledge about the genetic variability within different S. aureus populations would help in the design of efficient treatments.
The LOGIC trial is evaluating the combination of capecitabine/oxaliplatin ± lapatinib as first-line therapy for HER2 overexpressing EGCs.
Strikingly, one trial evaluating the combination of temozolomide, radiotherapy and erlotinib was discontinued due to unacceptable toxicity [ 39].
A phase 1 study evaluating the combination of bexarotene with EFA in solid tumors is currently recruiting patients (NCT01504490).
Trials evaluating the combination of nivolumab (NCT01454102) or ipilimumab (NCT00790010) with bevacizumab are ongoing (http://clinicaltrials.gov).gov
